Healthy Clinical Trial
Official title:
The Influence of Intranasal Oxytocin on Communication
| Verified date | April 2019 |
| Source | University of British Columbia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study investigates whether oxytocin, a neuropeptide known for its role in social bonding, influences the outcomes of persuasive communications and several primary evolutionary goals. Participants will be given either oxytocin or placebo on their first visit and then they will receive the other spray during their second visit. At each visit, participants will engage in several psychosocial tasks to assess the role of oxytocin on receptiveness to opposing opinions, navigating the spatial environment, mating and parenting goals. Participants' attitudes and behaviours will be compared across the different conditions.
| Status | Completed |
| Enrollment | 50 |
| Est. completion date | December 12, 2018 |
| Est. primary completion date | December 12, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: Healthy adult volunteers Exclusion Criteria: - Currently have a diagnosed mental illness or are in psychiatric or psychotherapeutic treatment. - Are taking endocrinologically or psychoactive drugs (e.g. psychotropic drugs such as antipsychotics, antidepressants, sedatives, or sleeping pills) - Are taking anti-hypertensive drugs or drugs with QTc prolongation - Abuse drugs or alcohol - Suffer from any significant medical illness, such as heart disease/cardiovascular disease, kidney disease, endocrinological disorders, or neurological disorders. - Are not found to be physically healthy after a required prescreen questionnaire created by a doctor - Allergic to preservatives (e.g. paragons) found in nasal sprays - Pregnant/breastfeeding - Are currently involved in other clinical studies in which drugs are administered. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Kenny Psychology Building | Vancouver | British Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| University of British Columbia | Natural Sciences and Engineering Research Council, Canada |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Communication Outcomes | Participants will answer a series of questions regarding their reactions (e.g., anger, receptiveness) to the speakers and the opinions presented in the photos. It is expected that when participants receive oxytocin they will be more receptive to opposing opinions compared to when they receive the placebo. Participants may also have differing levels of receptiveness depending on whether the person expressing the opinion comes from their ingroup or outgroup. | 60-90 minutes | |
| Secondary | Appetite | We predict that when participants receive oxytocin they will spend less time looking at photos of food compared to when they receive the placebo. | 60-90 minutes | |
| Secondary | Short vs. Long-Term mating orientation | When participants receive oxytocin they will spend more time looking at human infants, less time looking at attractive opposite sex others (especially the bodies of those opposite sex others; additionally, they will exhibit lower testosterone reactivity to images of attractive opposite sex targets and report weaker desires to engage in short-term romantic relationships in general. | 60-90 minutes | |
| Secondary | Peripheral narrowing of attention | When participants receive oxytocin they will exhibit less peripheral narrowing on a computerized visual attention task compared to when they receive a placebo. | 60-90 minutes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |